Radical Life Extension group
The Radical Life Extension group is an international team of scientists and entrepreneurs.

We are solving the practical challenge of radical extending life 
And, frankly, we really hope to solve this problem within our own lifetime.
Who are we? Main team of RLE group
Yuri Khait
"Anything less than immortality is a complete waste of time!" (Futurama). Yuri took this joke literally and decided that he had to beat aging first."

IT-entrepreneur, master's in engineering.

About 10 years ago, I became so interested in the question of life extension that it gradually became my top priority in life .

In 2013, together with other associates, I created an informal structure, which eventually evolved into the RLEgroup project.

In 2015, I became one of the founders and ideologists of the largest Russian-language network project "Technologies of Longevity", which currently has about 160,000 subscribers.

Alexander Fedintsev
"Every natural science contains as much truth as much mathematics it contains." Alexander agrees with Immanuel Kant and first learned how to evaluate the rate of aging mathematically."

Scientist and Machine Learning Engineer. Scientific background is in the field of bioinformatics, statistics and machine learning. Speaker of a number of international biogerontology conferences.

He has a Master's degree in computer technology from “Moscow Power Engineering Institute". Later he had a position of bioinformatics engineer in the Institute of Antimicrobial Chemotherapy.

Collaborates with Prof. A.A. Moskalev and his aging research laboratory. He has developed a highly accurate non-invasive biomarker of aging based on cardiovascular markers.

His current research interest is mainly focused on the role of the extracellular matrix (ECM) in the aging process.
Stanislav Polozov
He would invent everything in this world, but now Stanislav is busy solving the problem of how people do not die….

After graduating with a Master's degree in computational biology from Kiev State University, Department of Molecular Biology and Genetics, I worked in the Institute of Molecular Oncology at the Hannover Medical School (MHH), Germany.

At that time I started to make my first engineering inventions (for today I have more than 100 of them), e.g. computer display with subtractive color mixing (DE4443470A1), which principle is used in the latest display technologies.

Later I was engaged in several high-tech and scientific projects. While working for the biomedical investment fund "Angelico Ventures", I’ve provided several major transactions in the biopharmaceutical market.
Nikolay Sidorov
"The best clinical trial is self-trial. Following this principle, Nikolai has every chance to become the first ageless person on Earth."

Nikolay has a master's degree in psychology from Yaroslavl State University. Being a skilled spin doctor, he worked in the highest state bodies of the Russian Federation, ex-vice-governor of the Primorsky Krai of the Russian Federation.

He is a member of the board of the Foundation for Technological Modernization and Development.

Currently he is an entrepreneur, investor in the field of medicine and biotechnology, researcher of new approaches and antiaging therapies.
There’s gonna be a lot of important and really serious stuff about how we achieve a radical life extension.
Our values
A clear goal
Slowing down aging and its “rollback” is the immediate goal on the way to achieving unlimited longevity. We believe that complete victory over aging is real.
Science and technology.
We rely only on the achievements of science and technology.

Persistent movement
We follow a strategy of small, regular, practical steps in the right direction.
Risk analysis
We analyze all health and longevity risks, and do our best to exclude the most important ones.
We realize that time is short. And so we move to the goal as quickly as possible.
We give priority to what can be used in the near future.
Why we are so unique
Our projects cover all the full range of major aging issues: cardiovascular problems, cancer, dementia, metabolic disorders, sarcopenia, and other pathologies.
We do not focus on any single cause or pathological process. Aging is a complex, multifactorial problem. It cannot be solved by acting on only one side.
Our long-term focus is to investigate the impact of the structural disturbances of extracellular matrix and other "long-lived" proteins on aging of the body. In our opinion, these processes can make the greatest contribution relative to other known aging mechanisms.
Our vision for defeating aging
We believe in the possibility of complete victory over aging. It means:
Reducing the risks of disease and death to the level of a healthy person, and maintaining this level in the future.
Achievement of the functionality of organs and tissues, appearance and general condition up to the age of 25-30 years
An inexhaustible or regularly replenished source of inner strength
But this will not happen soon. We and our comrades-in-arms need to banally "live up" to that time. How can this be achieved?
For this we have developed a roadmap.

Our roadmap for the next 50 years

Stage 1
First stage (currently being implemented)
Goal: not to die from an age-dependent disease, keeping your body as healthy as possible.
What has already been achieved
Low impact on life expectancy. The combination of several effective techniques from our near-future portfolio can extend life
Available right now. Healthy lifestyle, dietary supplements, off-label use of well-known drugs and techniques
Find effective use of existing simple tools and techniques.
We already have a lot of practical experience in reducing the risks of age-related diseases.
Stage 2
Second stage (next 3-10 years)
Task: To ensure practical access to personalized therapies, minimizing the risks of all age-related pathologies, as well as the means to track these risks.
What will be achieved
Development and introduction into clinical practice of “strong” tools to influence life expectancy. Maximum reduction of age risks and approaching the biological maximum of the human body. This stage does not yet provide a slowdown in aging and an increase in maximum life expectancy.
Means of achieving
  • gene therapy aimed to rejuvenate blood vessels, heart, kidneys, brain etc.
  • gene therapy to combat fat accumulation and protect against type 2 diabetes, etc.
  • restoration of elastin in the extracellular matrix of skin, joints, vessels, lungs, heart.
  • stem cell pool rejuvenation therapy.
  • therapy to combat sarcopenia.
A portfolio of projects for the next 2-3 years is completed
Stage 3
Third stage (next 10-25 years)
Task: To influence the basic mechanisms of aging, to stop and rollback aging processes, to increase the maximum life expectancy.
What will be achieved
Real ways of influencing the aging process, showing aging retardation through specific biomarkers.
Means of achieving
Currently unknown, their search is one of the intermediate most important tasks.
Creation of scientific and organizational structures to search for ways to defeat aging and to practically implement those methods.
We have started the creation of a roadmap for the first phase of research needed to defeat aging and create a “longevity risk management system”.

We are not the greatest experts in packing our extensive anti-aging experience into a nice website, we will get to that later. But we do have a vision for our development and goals.

Our current priorities: scientific research, analysis of the current situation in biogerontology and related sciences, experimental proof of hypotheses.

How we achieve goals
We’ve created and regularly update a list of near-term projects for the second and third stages (collecting emerging hypotheses).
We conduct research to test scientific hypotheses and for further patent protection. Funds are being raised for these studies.
We create a scientific structure to conduct research work. Also look for new contract laboratories and researchers.
We form Advisory & Science Boards of high quality professionals.
We develop a staff training system to work in our scientific and commercial structures.
Constantly and consistently expand the field of scientific and analytical research.

We’ve created our project in 2015 and this is what we’ve managed to do in past 6 years:

Milestones of RLE group
Spring 2015: the first fact sheets of the effectiveness of lifestyle factors and geroprotectors
Summer 2015: the first fact sheets of the effectiveness of lifestyle factors and geroprotectors
Autumn 2015: creation of the info-project "Technologies of Longevity" with the aim to promote the ideas of RLE to a wide audience. At present, the project continues to be successfully developed by a group of interested parties.
Spring 2016: creation of the analytical group to collect the latest research results around the world.
Spring 2016: getting the first successful practical result. The first clinical trial of the combination of "sartans + statins" and instrumental confirmation of atherosclerosis reduction. By now, the protocol is essentially improved. In 2021, this protocol was officially adopted by the Russian Society of Cardiology.
2017: the audience of the project reached 200,000 people
2018: creation of the scientific group to test the latest research results collected around the world.
2019: First meetup of project members in Spain. International status of the project.
2020: Completion of a portfolio of pilot projects, which implementation will help to significantly affect life expectancy, both through reducing the risks of age-related diseases (cardiovascular diseases, cancer, dementia, metabolic disorders, etc.), and through the basic mechanisms of aging.
Spring 2020: the first practical biological experiment, the launch of the first stage of a project to create an antiaging gene therapy.
Autumn 2020: the practical experiment with plasmapheresis according to Irina Konboy's protocol. And than in Summer 2021, start of official clinical trials in plasmapheresis under the scientific supervision of Prof. A. Moskalev.
2021: continuation of the series of experiments to create antiaging gene therapy, an experiment on epigenetic rejuvenation of hematopoietic stem cells

The scientific audience likes the Hirsch index, so sometimes Alexander Fedintsev publishes some of the results of his scientific work.

Scientific publications with the participation of Alexander Fedintsev in the field of biogerontology:
Moskalev, A., Chernyagina, E., Tsvetkov, V., Fedintsev, A., Shaposhnikov, M., Krut'ko, V., ... & Kennedy, B. K. (2016). Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic. Aging cell, 15(3), 407-415.
Moskalev, A., Shaposhnikov, M., Proshkina, E., Belyi, A., Fedintsev, A., Zhikrivetskaya, S., ... & Kudryavtseva, A. (2016). The influence of pro-longevity gene Gclc overexpression on the age-dependent changes in Drosophila transcriptome and biological functions. BMC genomics, 17(14), 273-289

Fedintsev, A., Kashtanova, D., Tkacheva, O., Strazhesko, I., Kudryavtseva, A., Baranova, A., & Moskalev, A. (2017). Markers of arterial health could serve as accurate non-invasive predictors of human biological and chronological age. Aging (Albany NY), 9(4), 1280.
Fedintsev, A., & Moskalev, A. (2020). Stochastic non-enzymatic modification of long-lived macromolecules-A missing hallmark of aging. Ageing Research Reviews, 62, 101097
What they write about us in the press:
A recent article in “Fortune” magazine about the prospects for overcoming aging fortune.com/2020/12/30/anti-aging-research-health-care-spending-biden refers, among others, to the work of our group member A.Fedintsev, where one of the main causes of aging is damage to long-lived proteins of the extracellular matrix.
About our experiment: Biohackers Perform First Plasma Dilution Experiment on Humans (Lifespan.io)
The main idea:
"You will all die without us! And with us you have a chance ..."
(A. Fedintsev)

In order to move faster and more effectively towards our goal, we organize thematic events ourselves or participate in such events as invited guests.

The following persons are involved in the project together with us:
Advisory board:
Andrey Isaev
Founder and CEO one of the largest Russian commercial laboratory network “DNKOM” and the network of medical centers “Medgorod”. Pediatrician, graduated from the Russian State Medical University in 2006. He worked in the department of infectious diseases in Moscow Morozov Children's Hospital. After that he was the head of the commercial division of the Central Research Institute of Epidemiology. In 2009 he organized his own project.
He is the author of a number of scientific and medical studies, including the first in Russia study of the dynamics of the development of the immune response in patients with Covid-19. Research interests - anti-age medicine, anti-aging.
Evgeny Kovalev
A psychiatrist, practitioner of preventive and anti-aging medicine. He has deep versatile knowledge in classical medicine and extensive experience in managing patients with chronic diseases. Graduated from the Russian State Medical University in 2004. At the same time he collaborated with several medical publications in editorial positions. Worked as deputy chief physician at Children's Clinical Hospital 38 in Moscow, then moved to the Ministry of Health of the Russian Federation, the Federal Medical Biological Agency. In 2013 he became co-founder and chief physician of a private clinic. In recent years has held executive positions in the medical cluster of the insurance company Sogaz. Additional education - psychiatry, MBA, public administration and others.
Professional scientific interests include molecular mechanisms of life extension, expertise and consulting in biohacking, development of new treatment regimens for mental disorders and substance abuse, food addictions.
Science board:
Alexey Moskalev
Russian scientist-biogerontologist, specialist in the field of genetics of longevity and aging, studies the mechanisms of regulation of the rate of aging and longevity. Doctor of Biological Sciences, Professor, Professor of the Russian Academy of Sciences, Corresponding Member of the Russian Academy of Sciences.
Graduated from Syktyvkar State University. He works at the Institute of Biology of the Ural Branch of the Russian Academy of Sciences, the Gerontological Research and Clinical Center and the Institute of Molecular Biology named after V.I. V.A. Engelhardt. He headed the department at Syktyvkar State University, headed the laboratory of genetics of life expectancy and aging at the Moscow Institute of Physics and Technology. In 2016 he was elected a corresponding member of the Russian Academy of Sciences. Vice-President of the Gerontological Society at the Russian Academy of Sciences, member of the Central Council of the Vavilov Society of Geneticists and Breeders.
Author of many scientific and popular science books on longevity and aging, and many scientific articles in the field of aging genetics, life span genetics and radiation genetics.
Member of the editorial boards of scientific journals: Aging Research Reviews, Biogerontology, Aging, Frontiers in Genetics, Gerontology, Aging and disease, Stem Cell Reviews and Reports, Advances in Gerontology and others.
Since 2008, he has been organizing the annual international conference on aging and longevity.
Leon Peshkin
Lecturer in the Department of Systems Biology at Harvard Medical School, also part of the Marine Biological Laboratory. He holds a PhD in Artificial Intelligence from Brown University and an MA in Applied Mathematics from the Weizmann Institute of Science. Current research interests include embryology, evolution and aging. Leon's research on aging and personal history was highlighted in a recent Boston Globe article. His personal genome is used as the human genome standard by the US National Standards Institute in the Genome in a Bottle program, as described in an article in the journal Genome. Leon's research on the use of artificial intelligence in the biology of aging was highlighted in an interview with the Life Extension Advocacy Foundation and Longevity Technology.
We also look for like-minded partners who, like us, want not to die.
If you've read up to here and also:
Want to extend your life and the lives of your loved ones as soon as possible
Want to contribute to the victory over aging
Personally motivated to defeat aging using scientific technology
Focused on practical results (increasing life expectancy and improving its quality), rather than quick profits
Appreciate the openness and transparency of cooperation
Inquisitive, ready to learn, to understand new things for yourself
Ready to become a member of our community
Then look what kind of partners we look for
Financial partners, investors.

This collaboration involves the following participation:

In the non-commercial part of the project - through an non-profit organization:

  • creation and maintenance of the work of a non-profit organization,
  • financing of the scientific work,
  • translation of articles into other languages
  • registration of IP (patents, etc)

In the commercial part:

  • Partners in this part are essentially "business angels" who fund projects at a very early, pre-clinical stage.
  • Equity-based commercial startups.
  • We are also ready to discuss strategic partnerships on an individual basis, taking into account your interests and goals.

If you would like to offer a financial cooperation - please contact us: we@rlegroup.net

Coauthors of biomedical experiments.
Сотрудники или руководители научных лабораторий, в основном молекулярно-биологического, биохимического профиля.

Heads and employees of scientific labs, mainly profiled in molecular biology and biochemistry.

Terms of cooperation:

  • on a paid basis from our side
  • with the potential to publish and participate in the formation of intellectual property

We are interested in any opportunities of cooperation with labs. Therefore, if our values are close to you, but you do not yet know exactly what you would like to offer, contact us anyway. We will consider any possible ways of cooperation, including non-public ones: we@rlegroup.net

For all participants in our project we:

  • we provide access to classified information about our current activities, plans, results, biohacker protocols, etc
  • we give the opportunity to receive services at cost price.
  • financial partners have a priority right to participate in investing of commercial projects.

If you know someone who would be interested in partnering with us, please let him know about our project.

We are always glad to cooperation and open to communication

You can read our reviews here (only russian)
Made on